Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07223047 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
A Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC), sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 252
- Enrollment target
- 8
- Study locations
NCT07223047: Recruiting Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC), sponsored by Bristol-Myers Squibb.
NCT07223047 is a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC) that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 252 participants, below the 281-participant average among 59 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (10% lower). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07223047, a Phase 1 study of Non-small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC), is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 252 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Cetuximab
- DRUG Nab-Paclitaxel
- DRUG Gemcitabine
- DRUG BMS-986523
Study Locations (8)
Maryland
- Local Institution - 0009 - Baltimore
Texas
- NEXT Oncology - San Antonio
Utah
- START Mountain Region - West Valley City
Virginia
- NEXT Virginia - Fairfax
British Columbia
- Local Institution - 0002 - Vancouver
Ontario
- Local Institution - 0010 - Toronto
Barcelona [Barcelona]
- Local Institution - 0006 - Badalona
Madrid
- Local Institution - 0008 - Hortaleza
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 252 participants |
| Start Date | 2025-11-25 |
| Est. Completion | 2028-10-13 |
| Phase | Phase 1 |
What NCT07223047 shows while recruiting
NCT07223047 is an interventional study that assigns participants to a tested intervention. The registered 252 participants enrollment target is mid-sized for trials with a published cap, below the 281-participant average among 59 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (10% lower).
The record links to 4 conditions, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT07223047 lists 8 locations in 8 states (Maryland, Texas, Utah).
Frequently Asked Questions
What is clinical trial NCT07223047 about?
NCT07223047 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies". The purpose of this study is to evaluate the safety, tolerability, and efficacy of BMS-986523 alone and in combination with anti-cancer agents in participants with advanced solid malignancies
What is the current status of trial NCT07223047?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 252 participants. The study started on 2025-11-25. Estimated completion is 2028-10-13.
What conditions does trial NCT07223047 study?
This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Malignancies.
What interventions are being tested in trial NCT07223047?
The interventions under investigation include: Pembrolizumab (DRUG), Cetuximab (DRUG), Nab-Paclitaxel (DRUG), Gemcitabine (DRUG), BMS-986523 (DRUG).
Who is sponsoring clinical trial NCT07223047?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07223047 being conducted?
This trial has 8 study locations across Maryland, Texas, Utah, Virginia, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-small Cell Lung Cancer (NSCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07223047's enrollment target sits among peer trials
252 23rd of 59 higher than 37 of 59 other Non-small Cell Lung Cancer (NSCLC) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-small Cell Lung Cancer (NSCLC) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 1
-
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02314988 · 252 participants · Phase 2
Tranexamic Acid to Reduce Blood Loss in Spine Surgery
- NCT03941756 · 252 participants · NA
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
- NCT05219617 · 252 participants · Phase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
- NCT05384158 · 252 participants · NA
Valuation in Depressed Mood, Anhedonia, and Anxiety
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI